Bafna Pharmaceuticals Ltd.
NSE: BAFNAPH | BSE: 532989
₹149.33
₹-7.85
(-4.99%)
As on 16-Jun-2026 11:33IST
Market cap
₹355 Cr
Revenue (TTM)
₹151 Cr
P/E Ratio
32
P/B Ratio
3.7
Div. Yield
0 %
Quality Score
2/10
Growth Score
6/10
Valuation Score
4/10
Momentum Score
10/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹11 Cr
-
ROE
5 %
-
ROCE
6.3 %
-
Industry P/E
34.74
-
EV/EBITDA
18.9
-
Debt to Equity
0.2
-
Book Value
₹40.6
-
EPS
₹4.7
-
Face value
10
-
Shares outstanding
23,656,335
10 Years Aggregate
CFO
₹-10.49 Cr
EBITDA
₹7.63 Cr
Net Profit
₹-38.87 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bafna Pharma
| -0.9 | 10.4 | 50.6 | 100.6 | 8.1 | 0.9 | -6.3 |
|
BSE Healthcare
| 8.1 | -0.5 | 9.8 | 6.7 | 23.6 | 13.1 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Bafna Pharma
| 82.1 | -15.2 | -8.7 | -34.0 | -9.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bafna Pharma
|
149.3 | 355.1 | 150.6 | 11.1 | 6.6 | 11.9 | 32 | 3.7 |
| 3,051.0 | 38,202.8 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 36.2 | 8.4 | |
| 8,461.0 | 21,002.6 | 2,275.6 | 187.5 | 10.3 | 22.9 | 112 | 24.1 | |
| 2,382.4 | 18,142.9 | 2,187.2 | 649.7 | 31.5 | 19 | 28.3 | 5.1 | |
| 1,734.1 | 10,721.4 | 1,196.4 | 149.4 | -- | 27.5 | 57.9 | 14.4 | |
| 1,370.3 | 19,248.4 | 3,129.4 | 647.4 | 26.9 | 18.1 | 31.1 | 4.9 | |
| 2,195.4 | 35,734.0 | 4,147.8 | 709.5 | 22.3 | 19.1 | 50.4 | 8.6 | |
| 4,521.3 | 20,771.5 | 2,519.7 | 722.4 | 33.6 | 18.8 | 28.8 | 4.9 | |
| 6,221.0 | 10,337.2 | 1,408.0 | 326.9 | 30.8 | 57.1 | 31.6 | 19.7 | |
| 527.2 | 10,489.1 | 1,538.1 | 226.2 | 20.4 | 9 | 43.1 | 4.0 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Bafna Pharma
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries.... Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP. Read more
-
Incorporated
1995
-
Chairman
--
-
Managing Director
--
-
Headquarters
Chennai, Tamil Nadu
-
Website
Looking for more details about Bafna Pharmaceuticals Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Bafna Pharma
What is the current share price of Bafna Pharmaceuticals Ltd Today?
The share price of Bafna Pharmaceuticals Ltd is ₹149.33 (NSE) and ₹150.10 (BSE) as of 16-Jun-2026 11:33 IST. Bafna Pharmaceuticals Ltd has given a return of 8.09% in the last 3 years.
What is the current PB & PE ratio of Bafna Pharmaceuticals Ltd?
The P/E ratio of Bafna Pharmaceuticals Ltd is 31.99 times as on 16-Jun-2026, a 8 discount to its peers’ median range of 34.74 times.
The P/B ratio of Bafna Pharmaceuticals Ltd is 3.69 times as on 16-Jun-2026, a 25 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
42.73
|
2.09
|
|
2024
|
24.68
|
2.24
|
|
2023
|
17.24
|
2.66
|
|
2022
|
57.59
|
4.85
|
|
2021
|
55.74
|
5.72
|
What is the 52 Week High and Low of Bafna Pharmaceuticals Ltd?
The 52-week high and low of Bafna Pharmaceuticals Ltd are Rs 213.36 and Rs 73.01 as of 16-Jun-2026.
What is the market cap of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has a market capitalisation of ₹ 355 Cr as on 16-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bafna Pharmaceuticals Ltd?
Before investing in Bafna Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.